Articles tagged with Crisprs
Researchers at Karolinska Institutet have developed a technique to deliver gene editors and protein therapeutics to cells using engineered extracellular vesicles. The method shows promising results in animal studies, highlighting the potential for treating genetic diseases and neurological disorders.
Mass General Brigham researchers developed a machine learning algorithm, PAMmla, to predict properties of genome editing enzymes. The approach helps reduce off-target effects and improves editing safety and efficiency, enabling customized enzymes for new therapeutic targets.
Tulane University scientists developed a handheld device to deliver rapid and accurate tuberculosis diagnoses in under an hour. The device, called the lab-in-tube assay (LIT), can detect Mycobacterium tuberculosis DNA in saliva, blood, and sputum samples, offering a cost-effective tool for improving TB diagnoses in resource-limited areas.
Researchers at KAIST discovered that DDX54 is the master regulator hindering immunotherapy's effectiveness in lung cancer. Supressing DDX54 enhances immune cell infiltration into tumors and improves immunotherapy efficacy.
Researchers have discovered a protective cloaking mechanism in jumbo phages that shield their genetic material from the host's immune system. This innovation could lead to new therapies for antibiotic-resistant infections.
Researchers developed a CRISPR-based diagnostic test that rapidly detects low levels of pathogen genetic material in blood without nucleic acid amplification. The test demonstrated unprecedented sensitivity and could be used to develop highly sensitive CRISPR-based diagnostic tests for detecting pathogens in minutes.
Researchers have discovered new CRISPR-Cas systems with improved efficiency and specificity, including one from dairy cow bacteria that can target specific gene sequences. The new systems have potential applications in human health, biotechnology and environmental fields.
A new method for detecting antibiotic resistance genes (ARGs) in wastewater has been developed by researchers, which uses CRISPR-Cas9 technology to enrich ARG fragments and increase detection sensitivity. This enhanced method was found to detect 1189 more ARGs and 61 more ARG families compared to standard metagenomics methods.
A breakthrough CRISPR-based test has been developed to diagnose Pneumocystis jirovecii pneumonia (PJP), a life-threatening fungal infection. The test detects RNA from live fungi in blood samples and throat swabs, providing a faster and more accurate diagnosis than current invasive bronchoscopy procedures.
Researchers use CRISPR-Cas9 to remove duplicate chromosomes in trisomy 21 cells, restoring gene expression and cellular phenotypes. The technique shows promise as a potential medical intervention for people with Down syndrome.
Researchers have discovered a new mechanism by which bacteria defend against CRISPR-Cas systems, and how phages counter these defenses. This discovery holds potential to enhance the safety and precision of CRISPR-based technologies.
Researchers discovered 47,350 active putative enhancers associated with Parkinson's disease, schizophrenia, and other neurological disorders. These enhancers were found to regulate gene expression during neuronal differentiation.
Scientists at Duke University have discovered a master epigenetic switch that can be activated using CRISPR to compensate for missing genes in Prader-Willi syndrome. This approach could potentially treat the disease by turning on naturally suppressed genes from one parent, addressing the underlying genetic defect.
Researchers used CRISPR/Cas9 to study the gene function of adenine phosphoribosyl transferase in beans. They found two functional mutants with distinct roles: one affects adenine recycling and the other regulates cytokinins, essential for root growth and nodules.
Researchers used CRISPR/Cas to generate controlled chromosomal inversions in Arabidopsis thaliana, finding no significant changes in epigenetic marks or gene expression. Only minor genome-wide effects were observed, indicating the robustness of the epigenome and transcriptome.
Researchers from the University of Lausanne used genome editing to repair a deleterious domestication mutation in the tomato genome. This resulted in an earlier yielding variety, which could have implications for agriculture and sustainability. The study demonstrates the potential benefits of genome editing for crop breeding.
Researchers at Gladstone Institutes and UCSF identified MED12 as a crucial switch that regulates T cell rest and activation. The study found that MED12 promotes rest in resting cells and activation in activated cells, and its removal led to blurred lines between rest and activation.
Researchers have discovered a major setback in the use of AZD7648 to promote precise gene editing, which causes massive genetic changes and genome instability. Despite this, scientists remain optimistic about advancing CRISPR-Cas technology to treat diseases.
Researchers at the University of Tokyo have developed a new CRISPR-based system to label small extracellular vesicles (sEVs) with RNA barcodes, enabling comprehensive analysis of their biogenesis and release regulators. This system allows for the simultaneous study of thousands of genes and estimation of sEV release from host cells.
Researchers have developed a new CRISPR-Cas method to decipher the function of genetic variants that contribute to cancer. The approach creates tens of thousands of cells with different gene variants, allowing scientists to identify which variants make cancer cells resistant to standard drugs.
A new study uses CRISPR-Cas13 to identify nearly 800 noncoding RNAs that are functional and essential for cell function, including in cancer and human development. The researchers found that these RNA molecules modulate key pathways for cell proliferation and can serve as potential biomarkers and therapeutic targets for cancer treatment.
Researchers have discovered a new type of CRISPR chemistry that floods infected cells with toxic molecules and shuts down activity, preventing viruses from spreading. The discovery sheds light on the complex mechanisms of CRISPR systems and their potential applications as diagnostic tools for infection.
A CRISPR-Cas9 based gene editing therapy has been shown to reduce angioedema attacks and sustainably lower kallikrein levels in patients with hereditary angioedema, offering a potential treatment option. The therapy was tested on 27 patients across two dosages compared to placebo.
A team of researchers has developed strategies to identify regulators of intestinal hormone secretion, which could lead to new treatments for metabolic and gut motility disorders. They used human organoids to study the function of 'nutrient sensors' on hormone-producing cells in the gut.
Researchers at ChristianaCare Gene Editing Institute use CRISPR tools to safely disable gene mutation linked to treatment-resistant melanoma. The approach targets melanoma tumor cells while leaving healthy cells alone, restoring sensitivity to anticancer drugs.
Scientists at St. Jude Children's Research Hospital studied the structure of Fanzor2, a eukaryotic genome-editing protein, to understand its potential for gene editing. The findings reveal that Fanzor2 has a unique RNA-guided nuclease system, which could be harnessed to create more functional and smaller proteins.
The CRISPR-Cas13 system enables temporary gene expression manipulation without permanent genomic changes, holding promise for treating diseases caused by RNA defects. It has been applied to correct mutations linked to Duchenne muscular dystrophy and can be used to alter splicing events, making it a powerful tool in personalized medicine.
Researchers developed a compact 'gene scissor' tool, TnpB, which shows a 4.4-fold increase in efficiency of modifying DNA, making it more effective as a gene editing tool. The tool can be used to treat patients with familial hypercholesterolemia, reducing cholesterol levels by nearly 80%.
CREME, a new AI-powered virtual laboratory, allows scientists to run thousands of virtual experiments with the click of a button to identify key regions of the genome. This breakthrough may lead to discovering new therapeutic targets and giving scientists access to cutting-edge technology without a real laboratory.
Researchers at Osaka Metropolitan University used CRISPR/Cas9 to create a strain of Euglena that produces wax esters with shorter carbon chains, improving their cold flow and suitability as a biofuel feedstock. This breakthrough could potentially replace petroleum-based production of wax esters with biological sources.
A new method called VitelloTag has been developed at the Marine Biological Laboratory, allowing researchers to deliver miniature research tools into egg cells and embryos. The approach uses a yolk protein found in most animals to bind to the receptor on the egg cell surface, enabling efficient delivery of CRISPR-Cas9.
A team of international researchers has discovered a surprising genetic mechanism that influences the vibrant patterns on butterfly wings. An RNA molecule controls where dark pigments are made during butterfly metamorphosis, shaping the butterfly's color patterns in a way previously unforeseen.
Researchers at Montana State University have published a study in Nature describing the discovery of the PARIS immune system, which uses tRNA to neutralize viral infections. The team used advanced microscopy techniques to visualize the system's structure and function.
Michigan State University researchers have developed a method for CRISPR-based genome editing in Nile grass rats, which are diurnal rodents with sleep patterns similar to humans. This breakthrough could provide an alternative model for studying human health and disease, as existing models rely heavily on laboratory mice.
The CRISPR/Cas9 system has been adapted for genome visualization, enabling the study of chromatin dynamics and genome organization in living cells. Recent advancements have expanded its applications to live cell imaging, providing a robust tool for visualizing genomic loci.
A team of scientists has found that the same ancient gene family is responsible for prickles in multiple plants, including roses and eggplants. This discovery sheds light on convergent evolution and could have implications for understanding how similar traits emerge in different species.
A new CRISPR method, SEED/Harvest, has been developed to precisely modify DNA in fruit flies using the Single-Strand Annealing repair pathway. This allows for genome-wide changes with minimal unwanted scars.
Researchers have used CRISPR/Cas9 gene editing to improve groundcherry's growth habit and fruit characteristics. This breakthrough could lead to increased crop yields and reduce the need for pesticides. The study also highlights the potential of groundcherry as a model species for studying plant biology.
A team of scientists at the University of Sydney has repurposed a commonly used blood thinner, heparin, as an inexpensive antidote for cobra venom. The discovery could drastically reduce the impact of snakebites worldwide, particularly in low- and middle-income countries where cobra species account for most snakebite incidents.
Researchers have developed a new method called PUMA that uses CRISPR-Cas12 nucleases to detect RNA biomarkers. This technology overcomes limitations of existing methods by reprogramming tracrRNAs to recognize specific RNA targets, enabling precise detection without requiring a specific recognition sequence.
A team of researchers led by Professor Peter Fineran from the University of Otago discovered a novel regulatory mechanism in a protein used by phages to deploy anti-CRISPR. This finding has significant implications for understanding gene regulation and developing new antimicrobial therapies.
A team of scientists at Gladstone Institutes has developed a new method that enables them to make precise edits in multiple locations within a cell—all at once. They created a tool using molecules called retrons to efficiently modify DNA in bacteria, yeast, and human cells.
A breakthrough in chrysanthemum breeding uses CRISPR/Cas9 to enhance disease resistance and genetic research. The study establishes a reliable gene-editing system for chrysanthemums, which promises to advance genetic research and improve the breeding of ornamental plants.
A CHARMed collaboration has created a set of molecular tools called CHARMs that can turn off disease-causing genes, including those coding for the prion protein. The tools have shown promise in silencing the prion protein gene and improving or eliminating disease symptoms in animals.
Researchers at the University of Sydney have developed SeekRNA, a programmable tool that can precisely target and relocate genetic sequences with high accuracy and flexibility. This breakthrough technology surpasses current limitations of CRISPR, enabling more precise editing and reducing errors.
A new CRISPR-based paper strip test could allow more patients to get the right treatment for the flu, researchers say. The test distinguishes between different influenza types and can be reprogrammed to recognize other viruses.
A new plant gene drive system, CRISPR-Assisted Inheritance (CAIN), has been developed to enhance trait inheritance in plants. The system uses a toxin-antidote mechanism to override Mendelian inheritance, allowing for the spread of beneficial genes at higher rates.
New research reveals that CRISPR/Cas9 gene editing tools have biases against cells from people of African ancestry, leading to false negative results. The study's findings highlight the importance of increasing genetic diversity in large-scale cell line libraries to mitigate this bias.
A new, high-yielding variety of camelina has been engineered with a gene that increases oil production by 21.4%. The modified seeds have lower levels of flavonoid compounds and mucilage, but higher levels of genes involved in oil synthesis.
Researchers used CRISPR to fine-tune sugarcane's leaf angle, capturing more sunlight and increasing biomass production. The study focused on the LIGULELESS1 gene, which plays a major role in determining leaf angle.
Researchers from the University of Illinois have used CRISPR/Cas9 to alter the upstream regulatory DNA of a food crop, increasing gene expression and improving downstream photosynthesis. This approach, which does not require adding foreign DNA, has shown promising results in increasing photosynthetic activity in rice.
Researchers have developed a compact, high-fidelity version of the Cas12a protein, which can be packaged within a non-pathogenic virus for targeted gene editing. The modified protein demonstrates efficient editing activity and has been shown to reduce blood cholesterol levels in mice with high cholesterol.
Scientists at Gladstone Institutes used CRISPR interference to map the layered mechanisms controlling expression of key immune genes. The study provides valuable insights into immune balance, autoimmunity, and cancer immunotherapies, shedding light on genetic variants linked to disease risk and potential treatments.
Researchers from VIB-UGent Center for Plant Systems Biology improved multiplex mutagenesis, reducing the complexity and cost of large-scale genome editing projects. The team optimized CRISPR/Cas9 vector design, achieving a 99% mutation rate with high efficiency.
Researchers have uncovered a unique functionality of CRISPR-Cas Type IV systems, which can silence gene expression at target locations without cutting DNA. This discovery holds promise as a potential biotechnological application to combat antibiotic-resistant superbugs.
Researchers developed Cas9 variants to target non-canonical PAMs in Brassica, expanding genome editing capabilities. The SpRY variant showed high editing efficiency at near-PAM-less sites, enabling precise adenine base editing.
A phase 1/2 trial of CRISPR gene editing has demonstrated safety and efficacy, with measurable improvements in 11 out of 14 participants with a form of inherited blindness. The treatment, EDIT-101, was found to be clinically meaningful for four participants and showed significant improvements in cone-mediated vision.
A pioneering CRISPR gene editing trial has demonstrated significant improvement in vision for 79% of participants with inherited retinal degeneration. The study's findings support further research into the potential of CRISPR-based treatments for inherited blindness.
Researchers at the University of Trento have identified a collection of molecular tools to rewrite DNA, including a compact Cas9 enzyme from the human microbiome. The discovery has potential for gene therapy applications and could speed up the development of therapies for genetic diseases.
A team of scientists has developed a method to edit RNA in human cells using CRISPRs, which could lead to new treatments for genetic diseases. The breakthrough allows for the removal of mutations that cause cystic fibrosis and other diseases.